Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102

Movement Disorders Clinical Practice
Stuart H IsaacsonReed Johnson

Abstract

ADS-5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS-5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, but suboptimal durability and tolerability limit its clinical utility. In an ongoing, open-label, phase 3 study in the US and Western Europe (NCT02202551), patients with PD received 274 mg of ADS-5102 (equivalent to 340 mg amantadine HCl) once daily at bedtime for up to two years. Study outcomes included safety and assessment of motor complications, as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV. This manuscript focuses on those patients switched to ADS-5102 from amantadine IR. Results in two groups of patients who previously completed a randomized controlled trial (EASE LID or EASE LID 3) are also presented according to use of ADS-5102 or placebo in that study before enrollment in the open-label study. Change in MDS-UPDRS Part IV at week 8 was -0.3 in the previous ADS-5102 subgroup (n = 61), -3.4 in the previous placebo subgroup (n = 79), and -3.4 in the previous amantadine IR subgroup (n = 3...Continue Reading

References

May 30, 1970·Lancet·J D ParkesR P Knill-Jones
Feb 1, 1981·Antimicrobial Agents and Chemotherapy·F G HaydenB Giordani
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Jun 5, 2003·American Journal of Epidemiology·Stephen K Van Den EedenLorene M Nelson
Dec 21, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·S ThomasI Gottlob
Apr 10, 2007·Journal of Neural Transmission·T MüllerD A Haeger
Nov 2, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxCristina Sampaio
Jun 6, 2012·Journal of the Neurological Sciences·Dong-Churl SuhUsha Mallya
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
Jul 26, 2013·Brain : a Journal of Neurology·Jeffrey H KordowerRaymond T Bartus
Apr 24, 2014·JAMA : the Journal of the American Medical Association·Barbara S Connolly, Anthony E Lang
Jun 24, 2014·Parkinsonism & Related Disorders·Marlene C HechtnerRafael Mikolajczyk
Feb 5, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Rajesh PahwaMary Jean Stempien
Aug 24, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Wolfgang OertelMary Jean Stempien

❮ Previous
Next ❯

Citations

May 7, 2019·Expert Opinion on Pharmacotherapy·Thomas MüllerJan-Dominique Möhr
Jul 25, 2019·Drugs·Thomas Müller, Jan-Dominique Möhr
Oct 18, 2019·Expert Opinion on Drug Safety·Valentina LetaAngelo Antonini
Oct 15, 2021·CNS Drugs·Sarah MarmolJason Margolesky
Dec 18, 2021·Neurodegenerative Disease Management·Thomas Müller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.